Therapeutic targeting of Neu1 sialidase with oseltamivir phosphate (Tamiflu®) disables cancer cell survival in human pancreatic cancer with acquired chemoresistance

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 117-134

  O'Shea, Leah K ^a   Abdulkhalek, Samar ^a   Allison, Stephanie ^a   Neufeld, Ronald J ^a   Szewczuk, Myron R ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Cancer cell survival; Chemoresistance; Human pancreatic cancer; PANC1 cell lines

Indexed keywords

CISPLATIN; GEMCITABINE; NERVE CELL ADHESION MOLECULE; NEUL SIALIDASE; OSELTAMIVIR; SIALIDASE; UNCLASSIFIED DRUG; UVOMORULIN; VASCULAR ENDOTHELIAL CADHERIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER RESISTANCE; CANCER SURVIVAL; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; LIVER METASTASIS; LOW DRUG DOSE; LUNG METASTASIS; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PANCREAS CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; TUMOR XENOGRAFT;

EID: 84892538604     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S55344     Document Type: Article

References (72)

1. Maehara S, Tanaka S, Shimada M, etal. Selenoprotein P, as a predictor for evaluating gemcitabine resistance in human pancreatic cancer cells. Int J Cancer. 2004;112(2):184-189.
2. Shah AN, Summy JM, Zhang J, Park SI, Parikh NU, Gallick GE. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol. 2007;14(12):3629-3637.
3. Kabashima A, Higuchi H, Takaishi H, etal. Side population of pancreatic cancer cells predominates in TGF-beta-mediated epithelial to mesenchymal transition and invasion. Int J Cancer. 2009;124(12):2771-2779.
4. Konecny GE, Venkatesan N, Yang G, etal. Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. Br J Cancer. 2008;98(6):1076-1084.
5. Creighton CJ, Gibbons DL, Kurie JM. The role of epithelial-mesenchymal transition programming in invasion and metastasis: a clinical perspective. Cancer Manag Res. 2013;5:187-195.
6. Arumugam T, Ramachandran V, Fournier KF, etal. Epithelial to transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009;69(14):5820-5828.
7. Yang AD, Fan F, Camp ER, etal. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res. 2006;12(14 Pt 1):4147-4153.
8. Rho JK, Choi YJ, Lee JK, etal. Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer. 2009;63(2):219-226.
9. Zavadil J, Bottinger EP. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene. 2005;24(37):5764-5774.
10. Allington TM, Schiemann WP. The Cain and Abl of epithelial-mesenchymal transition and transforming growth factor-beta in mammary epithelial cells. Cells Tissues Organs. 2011;193(1-2):98-113.
11. Tian M, Neil JR, Schiemann WP. Transforming growth factor-beta and the hallmarks of cancer. Cell Signal. 2011;23(6):951-962.
12. Wendt MK, Smith JA, Schiemann WP. Transforming growth factor-beta-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression. Oncogene. 2010;29(49):6485-6498.
13. Taylor MA, Parvani JG, Schiemann WP. The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells. J Mammary Gland Biol Neoplasia. 2010;15(2):169-190.
14. Nagaraj NS, Datta PK. Targeting the transforming growth factor-beta signaling pathway in human cancer. Expert Opin Investig Drugs. 2010;19(1):77-91.
15. Katoh Y, Katoh M. Hedgehog signaling, epithelial-to-mesenchymal transition and miRNA. Int J Mol Med. 2008;22(3):271-275.
16. Olive KP, Jacobetz MA, Davidson CJ, etal. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324(5933):1457-1461.
17. Oliveira-Cunha M, Newman WG, Siriwardena AK. Epidermal growth factor receptor in pancreatic cancer. Cancers. 2011;3(2):1513-1526.
18. Chang ZG, Wei JM, Qin CF, etal. Suppression of the epidermal growth factor receptor inhibits epithelial-mesenchymal transition in human pancreatic cancer PANC1 cells. Dig Dis Sci. 2012;57(5): 1181-1189.
19. Danilov AV, Neupane D, Nagaraja AS, etal. DeltaNp63alpha-mediated induction of epidermal growth factor receptor promotes pancreatic cancer cell growth and chemoresistance. PLoS One. 2011;6(10): e26815.
20. Sette G, Salvati V, Memeo L, etal. EGFR inhibition abrogates leiomyosarcoma cell chemoresistance through inactivation of survival pathways and impairment of CSC potential. PLoS One. 2012;7(10):e46891.
21. Holz C, Niehr F, Boyko M, etal. Epithelial-mesenchymal-transition induced by EGFR activation interferes with cell migration and response to irradiation and cetuximab in head and neck cancer cells. Radiother Oncol. 2011;101(1):158-164.
22. Faller BA, Burtness B. Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy. Biologics. 2009;3:419-428.
23. Gilmour AM, Abdulkhalek S, Cheng TSW, etal. A novel epidermal growth factor receptor-signaling platform and its targeted translation in pancreatic cancer. Cell Signal. 2013;25(12):2587-2603.
24. Jayanth P, Amith SR, Gee K, Szewczuk MR. Neu1 sialidase and matrix metalloproteinase-9 cross-talk is essential for neurotrophin activation of Trk receptors and cellular signaling. Cell Signal. 2010;22(8): 1193-1205.
25. Abdulkhalek S, Amith SR, Franchuk SL, etal. Neu1 sialidase and matrix metalloproteinase-9 cross-talk is essential for Toll-like receptor activation and cellular signaling. J Biol Chem. 2011;286(42):36532-36549.
26. Abdulkhalek S, Guo M, Amith SR, Jayanth P, Szewczuk MR. G-protein coupled receptor agonists mediate Neu1 sialidase and matrix metalloproteinase-9 cross-talk to induce transactivation of TOLL-like receptors and cellular signaling. Cell Signal. 2012;24(11):2035-2042.
27. Amith SR, Jayanth P, Finlay T, etal. Detection of Neu1 sialidase activity in regulating Toll-like receptor activation. J Vis Exp. 2010(43).
28. Amith SR, Jayanth P, Franchuk S, etal. Neu1 desialylation of sialyl alpha-2,3-linked beta-galactosyl residues of Toll-like receptor 4 is essential for receptor activation and cellular signaling. Cell Signal. 2010;22(2):314-324.
29. Amith SR, Jayanth P, Franchuk S, etal. Dependence of pathogen molecule-induced toll-like receptor activation and cell function on Neu1 sialidase. Glycoconjug J. 2009;26(9):1197-1212.
30. Abdulkhalek S, Szewczuk MR. Neu1 sialidase and matrix metalloproteinase-9 cross-talk regulates nucleic acid-induced endosomal TOLL-like receptor-7 and-9 activation, cellular signaling and pro-inflammatory responses. Cell Signal. 2013;25(11):2093-2105.
31. Abdulkhalek S, Hrynyk M, Szewczuk MR. A novel G-protein-coupled receptor-signaling platform and its targeted translation in human disease. Research and Reports in Biochemistry. 2013;3:17-30.
32. Hata K, Koseki K, Yamaguchi K, etal. Limited inhibitory effects of oseltamivir and zanamivir on human sialidases. Antimicrob Agents Chemother. 2008;52(10):3484-3491.
33. Nan X, Carubelli I, Stamatos NM. Sialidase expression in activated human T lymphocytes influences production of IFN-gamma. J Leukoc Biol. 2007;81(1):284-296.
34. Tan AS, Berridge MV. Superoxide produced by activated neutrophils efficiently reduces the tetrazolium salt, WST-1 to produce a soluble formazan: a simple colorimetric assay for measuring respiratory burst activation and for screening anti-inflammatory agents. J Immunol Methods. 2000;238(1-2):59-68.
35. Du Z, Qin R, Wei C, etal. Pancreatic cancer cells resistant to chemoradiotherapy rich in "stem-cell-like" tumor cells. Dig Dis Sci. 2011;56(3):741-750.
36. Vestweber D. VE-cadherin: the major endothelial adhesion molecule controlling cellular junctions and blood vessel formation. Arterioscler Thromb Vasc Biol. 2008;28(2):223-232.
37. Voulgari A, Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta. 2009;1796(2): 75-90.
38. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871-890.
39. Hendrix MJ, Seftor EA, Meltzer PS, etal. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci U S A. 2001;98(14): 8018-8023.
40. Lillehoj EP, Hyun SW, Feng C, etal. Neu1 sialidase expressed in human airway epithelia regulates epidermal growth factor receptor (EGFR) and MUC1 protein signaling. J Biol Chem. 2012;287(11): 8214-8231.
41. Nath S, Daneshvar K, Roy LD, etal. MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes. Oncogenesis. 2013;2:e51.
42. Uemura T, Shiozaki K, Yamaguchi K, etal. Contribution of sialidase NEU1 to suppression of metastasis of human colon cancer cells through desialylation of integrin beta4. Oncogene. 2009;28(9):1218-1229.
43. Meuillet EJ, Mania-Farnell B, George D, Inokuchi JI, Bremer EG. Modulation of EGF receptor activity by changes in the GM3 content in a human epidermoid carcinoma cell line, A431. Exp Cell Res. 2000;256(1):74-82.
44. Zurita AR, Maccioni HJ, Daniotti JL. Modulation of epidermal growth factor receptor phosphorylation by endogenously expressed gangliosides. Biochem J. 2001;355(Pt 2):465-472.
45. Miljan EA, Meuillet EJ, Mania-Farnell B, etal. Interaction of the extracellular domain of the epidermal growth factor receptor with gangliosides. J Biol Chem. 2002;277(12):10108-10113.
46. Mirkin BL, Clark SH, Zhang C. Inhibition of human neuroblastoma cell proliferation and EGF receptor phosphorylation by gangliosides GM1, GM3, GD1A and GT1B. Cell Prolif. 2002;35(2):105-115.
47. Wang XQ, Sun P, Paller AS. Ganglioside GM3 blocks the activation of epidermal growth factor receptor induced by integrin at specific tyrosine sites. J Biol Chem. 2003;278(49):48770-48778.
48. Guan F, Handa K, Hakomori SI. Regulation of epidermal growth factor receptor through interaction of ganglioside GM3 with GlcNAc of N-linked glycan of the receptor: demonstration in ldlD cells. Neurochem Res. 2011;36(9):1645-1653.
49. Huang X, Li Y, Zhang J, Xu Y, Tian Y, Ma K. Ganglioside GM3 inhibits murine ascites hepatoma cell motility and migration in vitro through inhibition of phosphorylation of EGFR at specific tyrosine sites and PI3K/AKT signaling pathway. J Cell Biochem. 2013;114(7): 1616-1624.
50. Meuillet EJ, Kroes R, Yamamoto H, etal. Sialidase gene transfection enhances epidermal growth factor receptor activity in an epidermoid carcinoma cell line, A431. Cancer Res. 1999;59(1):234-240.
51. Kajiyama H, Shibata K, Terauchi M, etal. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol. 2007;31(2): 277-283.
52. Jo M, Lester RD, Montel V, Eastman B, Takimoto S, Gonias SL. Reversibility of epithelial-mesenchymal transition (EMT) induced in breast cancer cells by activation of urokinase receptor-dependent cell signaling. J Biol Chem. 2009;284(34):22825-22833.
53. Rezaei M, Friedrich K, Wielockx B, etal. Interplay between neural-cadherin and vascular endothelial-cadherin in breast cancer progression. Breast Cancer Res. 2012;14(6):R154.
54. Labelle M, Schnittler HJ, Aust DE, etal. Vascular endothelial cadherin promotes breast cancer progression via transforming growth factor beta signaling. Cancer Res. 2008;68(5):1388-1397.
55. Yamauchi M, Yoshino I, Yamaguchi R, etal. N-cadherin expression is a potential survival mechanism of gefitinib-resistant lung cancer cells. Am J Cancer Res. 2011;1(7):823-833.
56. Chang TH, Tsai MF, Su KY, etal. Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor. Am J Respir Crit Care Med. 2011;183(8):1071-1079.
57. Sanchez-Tillo E, Liu Y, de Barrios O, etal. EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness. Cell Mol Life Sci. 2012;69(20):3429-3456.
58. Peinado H, Quintanilla M, Cano A. Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal transitions. J Biol Chem. 2003;278(23):21113-21123.
59. Bolos V, Peinado H, Perez-Moreno MA, Fraga MF, Esteller M, Cano A. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci. 2003;116(Pt 3):499-511.
60. Medici D, Hay ED, Olsen BR. Snail and Slug promote epithelial-mesenchymal transition through beta-catenin-T-cell factor-4-dependent expression of transforming growth factor-beta3. Mol Biol Cell. 2008;19(11):4875-4887.
61. Strutz F, Zeisberg M, Ziyadeh FN, etal. Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Kidney Int. 2002;61(5):1714-1728.
62. Li JH, Huang XR, Zhu HJ, Johnson R, Lan HY. Role of TGF-beta signaling in extracellular matrix production under high glucose conditions. Kidney Int. 2003;63(6):2010-2019.
63. Zeisberg M, Bonner G, Maeshima Y, etal. Renal fibrosis: collagen composition and assembly regulates epithelial-mesenchymal transdifferentiation. Am J Pathol. 2001;159(4):1313-1321.
64. Blanco MJ, Moreno-Bueno G, Sarrio D, etal. Correlation of Snail expression with histological grade and lymph node status in breast carcinomas. Oncogene. 2002;21(20):3241-3246.
65. Jorda M, Olmeda D, Vinyals A, etal. Upregulation of MMP-9 in MDCK epithelial cell line in response to expression of the Snail transcription factor. J Cell Sci. 2005;118(Pt 15):3371-3385.
66. Yang J, Wahdan-Alaswad R, Danielpour D. Critical role of Smad2 in tumor suppression and transforming growth factor-beta-induced apoptosis of prostate epithelial cells. Cancer Res. 2009;69(6): 2185-2190.
67. Tian F, DaCosta Byfield S, Parks WT, etal. Reduction in Smad2/3 signaling enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. Cancer Res. 2003;63(23):8284-8292.
68. Hoot KE, Lighthall J, Han G, etal. Keratinocyte-specific Smad2 ablation results in increased epithelial-mesenchymal transition during skin cancer formation and progression. J Clin Invest. 2008;118(8): 2722-2732.
69. Hoot KE, Oka M, Han G, Bottinger E, Zhang Q, Wang XJ. HGF upregulation contributes to angiogenesis in mice with keratinocyte-specific Smad2 deletion. J Clin Invest. 2010;120(10): 3606-3616.
70. Sundqvist A, Ten Dijke P, van Dam H. Key signaling nodes in mammary gland development and cancer: Smad signal integration in epithelial cell plasticity. Breast Cancer Res. 2012;14(1):204.
71. Miyazono K, Suzuki H, Imamura T. Regulation of TGF-beta signaling and its roles in progression of tumors. Cancer Sci. 2003;94(3): 230-234.
72. Sundqvist A, Zieba A, Vasilaki E, etal. Specific interactions between Smad proteins and AP-1 components determine TGFbeta-induced breast cancer cell invasion. Oncogene. 2013;32(31):3606-3615.